Sign in
Active, not recruitingNo phase

Effects of Hypoglossal Nerve Stimulation on Cognition and Language in Down Syndrome and Obstructive Sleep Apnea

Key facts

Who runs it
Inspire Medical Systems, Inc.
Where
Atlanta, Boston, Cincinnati, Dallas, Madison, Norfolk, Philadelphia, and Pittsburgh, United StatesSee the 8 sites
Trial code
Status
Active, not recruiting
People taking part
57 people enrolled
Started
24 Jun 2021
Ended
30 Sept 2026
Type of study
Interventional
Treatments tested
  • Inspire Upper Airway Stimulation (UAS) System
Record updated
25 August 2026

Who can take part

Age
10 years to 21 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (23)Hide the full registry criteria

Who can take part

  • Diagnosis of Down syndrome
  • Age 10-21 years
  • Prior adenotonsillectomy
  • Severe OSA (AHI > 10, AHI < 50, no more than 25% AHI attributable to central events) based on prior in-lab PSG performed after adenotonsillectomy and within 18 months of enrollment
  • Approval from at least two of the three physician reviewers based upon the results of a routine drug-induced sleep endoscopy (DISE) having occurred within 12 months of enrollment
  • Subjects must have either tracheotomy or be ineffectively treated with CPAP due to non-compliance, discomfort, un-desirable side effects, persistent symptoms despite compliance use, or refusal to use the device
  • Children and their parents/guardians must be willing to have stimulation hardware permanently implanted, and be willing to participate in follow-up visits, postoperative PSG, and questionnaire completion
  • Children's parents/guardians must complete a questionnaire confirming that their child is capable of communicating feelings of pain or discomfort. They must also confirm they are able to assess their child for adverse effects related to device implantation
  • Children and their parents/guardians must be proficient in English

Who cannot take part

  • History of bleeding or clotting disorders and those on blood thinning or NSAID medications for the week prior to implantation surgery. Subjects will be asked to refrain from the use of NSAIDS for two weeks after implantation or any revision surgeries
  • Subject is currently taking muscle relaxant medication
  • Other medical conditions resulting in medical instability (eg. congestive heart failure, recent open heart surgery, immunosuppression, or chronic lung disease or aspiration)
  • Presence of another medical condition requiring future magnetic resonance imaging (MRI) of the chest
  • Subjects with a co-occurring diagnosis of autism spectrum disorder
  • Body mass index (BMI) above the 95th percentile for subject's age
  • Circumferential airway collapse at the level of the velopharynx observed during DISE
  • Patients with another implantable device which could interact unintentionally with the Inspire system
  • Any contraindication for general anesthesia
  • Life expectancy less than 12 months
  • Subject's inability to communicate pain or discomfort to their caretaker/parent, based on parental or investigator assessment
  • Nonverbal candidates will be excluded due to an inability to complete testing procedures including expressive language sampling
  • Subjects that have a positive β-HCG
  • Subjects deemed unfit for participation by the investigator for any other reason

Where in United States

  • Children's Healthcare of Atlanta/Emory University School of MedicineAtlanta, United States
  • Massachusetts General Hospital (Mass Eye & Ear Infirmary)Boston, United States
  • Cincinnati Childrens HospitalCincinnati, United States
  • University of Texas Southwestern/Children's Hospital of DallasDallas, United States
  • University of Wisconsin School of Medicine and Public HealthMadison, United States
  • Children's Hospital of the King's Daughters/East Virginia Medical SchoolNorfolk, United States
  • Children's Hospital of PhiladelphiaPhiladelphia, United States
  • Children's Hospital of PittsburghPittsburgh, United States

About the trial

What the trial wants to find out

This study is a prospective, single-arm study conducted under a common implant and follow-up protocol. The objective will be to follow fifty-seven (57) adolescents and young adults (10-21 years of age), with Down syndrome, moderate to severe sleep apnea, and post-adenotonsillectomy, for 12 months after undergoing implant of the Inspire Upper Airway Stimulation (UAS) System. The study is being conducted in order to evaluate objective change in cognition and expressive language after implant and therapy with the Inspire UAS System.

The group in the trial

  • Subjects implanted with Inspire UAS SystemTreatment being tested

    Subjects who meet eligibility criteria will be implanted with the Inspire Upper Airway Stimulation (UAS) System.

    Treatment: Inspire Upper Airway Stimulation (UAS) System

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
25 August 2026